Skip to main navigation Skip to search Skip to main content

Targeting GLP-1 receptor trafficking to improve agonist efficacy

  • Ben Jones
  • , Teresa Buenaventura
  • , Nisha Kanda
  • , Pauline Chabosseau
  • , Bryn M. Owen
  • , Rebecca Scott
  • , Robert Goldin
  • , Napat Angkathunyakul
  • , Ivan R. Corrêa
  • , Domenico Bosco
  • , Paul R. Johnson
  • , Lorenzo Piemonti
  • , Piero Marchetti
  • , A. M.James Shapiro
  • , Blake J. Cochran
  • , Aylin C. Hanyaloglu
  • , Asuka Inoue
  • , Tricia Tan
  • , Guy A. Rutter
  • , Alejandra Tomas
  • Stephen R. Bloom
  • Imperial College London
  • New England Biolabs, Inc.
  • Université de Genève
  • University of Oxford Medical Sciences Division
  • San Raffaele Scientific Institute
  • Vita-Salute San Raffaele University
  • Università di Pisa
  • University of Alberta, Faculty of Medicine and Dentistry
  • UNSW Medicine
  • Tohoku University

Research output: Contribution to journal › Article › peer-review

247 Citations (Scopus)

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion from pancreatic beta cells, causes weight loss, and is an important pharmacological target in type 2 diabetes (T2D). Like other G protein-coupled receptors, the GLP-1R undergoes agonist-mediated endocytosis, but the functional and therapeutic consequences of modulating GLP-1R endocytic trafficking have not been clearly defined. Here, we investigate a series of biased GLP-1R agonists with variable propensities for GLP-1R internalization and recycling. Compared to a panel of FDA-approved GLP-1 mimetics, compounds that retain GLP-1R at the plasma membrane produce greater long-term insulin release, which is dependent on a reduction in β-arrestin recruitment and faster agonist dissociation rates. Such molecules elicit glycemic benefits in mice without concomitant increases in signs of nausea, a common side effect of GLP-1 therapies. Our study identifies a set of agents with specific GLP-1R trafficking profiles and the potential for greater efficacy and tolerability as T2D treatments.

Original languageEnglish
Article number1602
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Targeting GLP-1 receptor trafficking to improve agonist efficacy'. Together they form a unique fingerprint.

Cite this